TY - JOUR T1 - Engineered CRISPR/Cas12a Enables Rapid SARS-CoV-2 Detection JF - medRxiv DO - 10.1101/2020.12.23.20248725 SP - 2020.12.23.20248725 AU - Long T. Nguyen AU - Santosh R. Rananaware AU - Brianna L.M. Pizzano AU - Brandon T. Stone AU - Piyush K. Jain Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/12/24/2020.12.23.20248725.abstract N2 - The coronavirus disease (COVID-19) caused by SARS-CoV-2 has swept through the globe at an unprecedented rate. CRISPR-based detection technologies such as DETECTR, SHERLOCK, and STOPCovid have emerged as a rapid and affordable platform that can shape the future of diagnostics. Recently, we reported engineered crRNAs for Cas12a, called ENHANCE, that enables enhanced detection of nucleic acids. Here we report development, clinical validation, and advancement of ENHANCE platform for detecting SARS-CoV-2. With an RT-LAMP pre-amplification step, ENHANCE detects samples down to a single copy with 95% accuracy and shows high specificity towards various isolates of SARS-CoV-2 against 31 highly similar and common respiratory pathogens. Utilizing LbCas12a-mediated trans-cleavage activity, ENHANCE works robustly in a wide range of magnesium concentration (3 mM-13 mM), allowing for further assay optimization. Additionally, ENHANCEv2 is developed to further improve the previously reported ENHANCE. ENHANCEv2 employs mutated LbCas12aD156R, engineered chimeric DNA-extended crRNA, and a dual reporter for both fluorescence-based reporter assay and lateral flow assay. Both ENHANCE and ENHANCEv2 are validated in 62 clinical nasopharyngeal swabs, showing 60/62 (96.7%) agreement with RT-qPCR results, and using only 5 μL of sample and 20 minutes of CRISPR reaction. Lateral flow assay on paper strips displays 100% agreement with fluorescence-based reporter assay in the clinical validation. Following a 30-minute pre-amplification RT-LAMP step, the lyophilized ENHANCEv2 is shown to achieve high sensitivity and specificity while reducing CRISPR reaction time to as low as 3 minutes and maintaining its detection capability upon storage at room temperature for several weeks.Competing Interest StatementP.K.J. and L.T.N. are listed as inventors on the multiple patent applications related to the content of this work.Funding StatementPortions of this work was supported by funds from the University of Florida (UF), the UF Herbert Wertheim College of Engineering, the United States-India Science & Technology Endowment Fund (USISTEF/COVID-I/247/2020), and the Florida Breast Cancer Foundation (AGR00018466).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was performed under the UF IRB protocol IRB202000781.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data associated with this study are in the main text and the Supplementary Materials. The CL7-tagged LbCas12a and LbCas12aD156R expression plasmid will be soon deposited to Addgene after obtaining the required permissions. ER -